Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALLONASDAQ:BTAINASDAQ:BYND On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLOAllogene Therapeutics$1.56-0.3%$1.86$1.32▼$4.58$338.06M1.023.10 million shs670 shsBTAIBioXcel Therapeutics$2.22-3.9%$3.26$1.72▼$49.58$7.12M0.891.16 million shs2,074 shsBYNDBeyond Meat$3.28-1.0%$3.69$2.86▼$10.31$250.09M2.362.97 million shs4,175 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLOAllogene Therapeutics-0.64%-4.29%-21.61%-28.77%-65.02%BTAIBioXcel Therapeutics+5.96%-2.12%+28.33%-63.34%-94.99%BYNDBeyond Meat+2.16%-4.61%-11.02%-18.87%-60.07%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALLOAllogene Therapeutics3.2383 of 5 stars3.52.00.00.03.44.20.6BTAIBioXcel Therapeutics4.6998 of 5 stars4.34.00.04.53.31.70.6BYNDBeyond Meat3.4872 of 5 stars2.73.00.03.42.11.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALLOAllogene Therapeutics 2.90Moderate Buy$9.29497.36% UpsideBTAIBioXcel Therapeutics 2.67Moderate Buy$42.601,818.92% UpsideBYNDBeyond Meat 1.33Strong Sell$4.9249.99% UpsideCurrent Analyst Ratings BreakdownLatest BYND, ALLO, and BTAI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/19/2025ALLOAllogene TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$9.00 ➝ $8.003/19/2025BTAIBioXcel TherapeuticsRODMAN&RENSHAWSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/19/2025BTAIBioXcel TherapeuticsRodman & RenshawSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$65.003/14/2025ALLOAllogene TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$10.00 ➝ $10.003/14/2025ALLOAllogene TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.003/14/2025ALLOAllogene TherapeuticsCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$5.002/27/2025BYNDBeyond MeatBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Perform ➝ Market Perform$6.00 ➝ $5.002/27/2025BYNDBeyond MeatBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderweight ➝ Underweight$4.00 ➝ $3.001/30/2025BTAIBioXcel TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$80.00 ➝ $48.001/7/2025BTAIBioXcel TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Underperform$112.00 ➝ $4.001/6/2025BTAIBioXcel TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$112.00 ➝ $80.00(Data available from 3/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALLOAllogene Therapeutics$22K15,356.69N/AN/A$3.04 per share0.51BTAIBioXcel Therapeutics$2.28M3.13N/AN/A($30.21) per share-0.07BYNDBeyond Meat$326.45M0.76N/AN/A($7.95) per share-0.41Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALLOAllogene Therapeutics-$327.27M-$1.33N/AN/AN/AN/A-52.13%-41.29%5/12/2025 (Estimated)BTAIBioXcel Therapeutics-$179.05M-$34.56N/AN/AN/A-3,119.33%N/A-105.04%4/1/2025 (Estimated)BYNDBeyond Meat-$338.14M-$2.43N/AN/AN/A-83.63%N/A-22.99%5/6/2025 (Estimated)Latest BYND, ALLO, and BTAI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/27/2025Q4 2024BTAIBioXcel Therapeutics-$4.36-$3.57+$0.79-$3.57$0.72 million$0.30 million3/13/2025Q4 2024ALLOAllogene Therapeutics-$0.34-$0.28+$0.06-$0.28$0.01 millionN/A2/26/2025Q4 2024BYNDBeyond Meat-$0.44-$0.65-$0.21-$0.65$76.08 million$76.66 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALLOAllogene TherapeuticsN/AN/AN/AN/AN/ABTAIBioXcel TherapeuticsN/AN/AN/AN/AN/ABYNDBeyond MeatN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALLOAllogene TherapeuticsN/A9.359.35BTAIBioXcel TherapeuticsN/A1.871.81BYNDBeyond MeatN/A3.431.99Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALLOAllogene Therapeutics83.63%BTAIBioXcel Therapeutics30.68%BYNDBeyond Meat52.48%Insider OwnershipCompanyInsider OwnershipALLOAllogene Therapeutics24.30%BTAIBioXcel Therapeutics21.20%BYNDBeyond Meat8.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALLOAllogene Therapeutics310217.27 million158.72 millionOptionableBTAIBioXcel Therapeutics903.21 million2.44 millionOptionableBYNDBeyond Meat88076.13 million59.60 millionOptionableBYND, ALLO, and BTAI HeadlinesRecent News About These CompaniesIQ EQ FUND MANAGEMENT IRELAND Ltd Sells 77,497 Shares of Beyond Meat, Inc. (NASDAQ:BYND)March 28 at 7:19 AM | marketbeat.comEnvironment-Friendly and Sustainable Food Market Outlook 2025-2029, Featuring Profiles of Key Players WhiteWave Foods Company, Amy's Kitchen, Earthbound Farm, Ben & Jerry's Homemade, and Beyond MeatMarch 27 at 10:53 AM | globenewswire.com5 Natural Foods Stocks to Buy for a Stable Portfolio in 2025March 26 at 9:31 AM | zacks.comBeyond Meat: How Will The Company Keep Paying For Its Losses?March 25 at 4:26 AM | seekingalpha.comBeyond Meat, Inc. (BYND) Stock ForecastsMarch 24, 2025 | finance.yahoo.comBest Health & Fitness Stocks to Buy for Strong GrowthMarch 24, 2025 | zacks.comBeyond Meat, Inc. (NASDAQ:BYND) Given Consensus Rating of "Strong Sell" by BrokeragesMarch 24, 2025 | marketbeat.comMcDonald's giving non-meat hamburger another try in CanadaMarch 21, 2025 | msn.comWhat Beyond Meat Got Wrong About The Future Of Plant-Based EatingMarch 20, 2025 | forbes.comInsider Selling: Beyond Meat, Inc. (NASDAQ:BYND) Director Sells 3,330 Shares of StockMarch 15, 2025 | marketbeat.comBeyond Meat, Inc. (NASDAQ:BYND) Director Sells $10,955.70 in StockMarch 15, 2025 | insidertrades.com2 AgriTech and Food Innovation Stocks to Buy for a Stable PortfolioMarch 14, 2025 | zacks.com3 Meat Stocks Worth Watching on Robust Industry OpportunitiesMarch 13, 2025 | zacks.comHow Beyond Meat and the plant-based meat industry lost their allureMarch 12, 2025 | msn.comWhy Beyond Meat and the plant-based meat industry couldn't live up to the hypeMarch 9, 2025 | youtube.comInvestors Purchase Large Volume of Beyond Meat Put Options (NASDAQ:BYND)March 7, 2025 | marketbeat.comSBI Securities Co. Ltd. Invests $382,000 in Beyond Meat, Inc. (NASDAQ:BYND)March 5, 2025 | marketbeat.comAll You Need to Know About Beyond Meat (BYND) Rating Upgrade to BuyMarch 3, 2025 | zacks.comBeyond Meat: Expecting Roughly Flat Revenue Growth For 2025March 2, 2025 | seekingalpha.comBeyond Meat stock trades in the red for seventh straight sessionMarch 1, 2025 | msn.comBMO Capital Markets Has Lowered Expectations for Beyond Meat (NASDAQ:BYND) Stock PriceFebruary 28, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines2 Energy Stocks to Play Both Sides of Tariff UncertaintyBy Jea Yu | March 5, 2025View 2 Energy Stocks to Play Both Sides of Tariff UncertaintyThese 3 Big Banks Are Set to Gain as Consumers Stash More CashBy Gabriel Osorio-Mazilli | March 7, 2025View These 3 Big Banks Are Set to Gain as Consumers Stash More CashOklo’s Stock Price Meltdown Is an Opportunity to BuyBy Thomas Hughes | March 25, 2025View Oklo’s Stock Price Meltdown Is an Opportunity to BuyHow to Protect Your Portfolio When Inflation Is RisingBy Sarah Horvath | March 10, 2025View How to Protect Your Portfolio When Inflation Is RisingSemtech Rallies on Earnings Beat—Is There More Upside?By Leo Miller | March 20, 2025View Semtech Rallies on Earnings Beat—Is There More Upside?BYND, ALLO, and BTAI Company DescriptionsAllogene Therapeutics NASDAQ:ALLO$1.56 -0.01 (-0.32%) As of 09:44 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.BioXcel Therapeutics NASDAQ:BTAI$2.22 -0.09 (-3.90%) As of 09:44 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.Beyond Meat NASDAQ:BYND$3.28 -0.03 (-0.97%) As of 09:44 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Beyond Meat, Inc., a plant-based meat company, develops, manufactures, markets, and sells plant-based meat products in the United States and internationally. The company sells a range of plant-based meat products across the platforms of beef, pork, and poultry. It sells its products through grocery, mass merchandiser, club stores, and natural retailer channels, as well as various food-away-from-home channels, including restaurants, foodservice outlets, and schools. The company was formerly known as Savage River, Inc. and changed its name to Beyond Meat, Inc. in September 2018. Beyond Meat, Inc. was incorporated in 2008 and is headquartered in El Segundo, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Archer Aviation Stock Sees Surge in Institutional Buys How Can Tomahawk 6 Contribute to Broadcom's AI Growth Story? Microsoft’s Big Malaysia Bet Could Pay Off for Investors Intuitive Machines Gains After Earnings Beat, NASA Missions Ahead Maybe It’s Time to Buy Some GameStop Stock Intel's Strategy to Win the Next AI Frontier Is Alphabet Too Cheap to Ignore After Its Recent Correction? Qualcomm Stock Is Coiling for a Breakout Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
